Further Phase II data for vTv Therapeutics Inc.’s leading glucokinase activator, TTP399, appear to lend support to the therapeutic strategy in improving glucose control in type 1 diabetics as an adjunct to insulin therapy.
Shares in the small High Point, NC-based firm shot up by more than 52% to $3.20 on the NASDAQ on the news on 10 February, as the second phase of the Simplici-T1 trial met its primary objective of improving blood sugar levels in 85 patients on optimized insulin therapy using either pumps or multiple daily injections of insulin